Inferra AIResearch Tools

Inferra AI / Company / TNGX

Tango Therapeutics, Inc.

TNGX · Health Care

Last earnings Aug 11, 2026

Key results

Collaboration revenuequarter

$3.2 million

Collaboration revenue was $3.2 million for the three months ended June 30, 2025, compared to $7.8 million for the same period in 2024, and $8.6 million for the six months ended June 30, 2025, compared to $14.2 million for the same period in 2024.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

AI analysis

Q2 2025 · reported Aug 5, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Collaboration revenue · Q2 2025
$3.2M
-59.0% vs year ago computed from stated figures
EX-99 · Aug 5, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Collaboration revenue$3.2 million—$7.8 million

EX-99 · Aug 5, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Liquidity and Capital Resources The Company expects that its existing cash, cash equivalents and marketable securities as of June 30, 2026 of $ 1.0 billion, will be sufficient to meet its current operating plan and fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these financial statements.

Treasury bills 24,884 24,884 Marketable debt securities U.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Tango Therapeutics, Inc. — Earnings release (2025-08-05)

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Liquidity and Capital Resources The Company expects that its existing cash, cash equivalents and marketable securities as of June 30, 2026 of $ 1.0 billion, will be sufficient to meet its current operating plan and fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these financial statements.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Treasury bills 24,884 24,884 Marketable debt securities U.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Treasury bills 4,970 4,970 Marketable debt securities U.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The following table summarizes the Company s marketable debt securities, classified as available-for-sale: Fair Value Measurements as of June 30, 2026 Amortized Cost Gross Unrealized Gains Gross Unrealized Loss Fair Value (in thousands) Marketable debt securities U.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Further, the Company did no t record any impairme nts to marketable securities or reserve s for credit losses related to its marketable debt securities during the periods then ended.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Strategy & priorities

“We plan to present efficacy and tolerability data from the ongoing TNG462 monotherapy Phase 1/2 study that will inform the initiation of a registrational study in pancreatic cancer next year and our development strategy in lung cancer.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This update is anticipated to provide sufficient information to inform the initiation of a registrational trial in pancreatic cancer next year and our development strategy for lung cancer.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

• The Phase 1/2 dose expansion trial is ongoing and TNG462 continues to be very well-tolerated at 250mg once-daily (QD) and below.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The trial is currently enrolling patients with MTAP-deleted solid tumors, with a focus on glioblastoma.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

TNG260, a first-in-class, highly selective CoREST complex inhibitor • Proof-of-mechanism has been established for TNG260 based on pharmacodynamic data from on-treatment patient biopsies, with favorable safety, tolerability and pharmacokinetic profiles shown at the expansion dose of 80 mg QD to date.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Risks & headwinds

Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Food and Drug Administration or other government agencies may slow the time necessary for new drugs to be reviewed and/or approved or prevent these agencies from performing business functions on which the operation of our business may rely (which could negatively impact our business); uncertainty around the U.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

presidential administration's approach to governmental agencies and/or product candidate approvals may present challenges for our business or create a more costly environment in which to pursue the development of new therapeutic candidates; our success depends on our ability to obtain and maintain patent and other proprietary protection for our technology and product candidates; and the scope of intellectual property protection obtained may not be sufficiently broad.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q.

SEC original ↗Tango Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 28 Item 1A.

SEC original ↗Tango Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Documents

Earnings deck slides

0 decks with slide view

Tango Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Tango Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Tango Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

34 documents

Earnings releases

9 documents

Presentations

3 documents

Transcripts

0 documents

No transcripts for Tango Therapeutics, Inc. are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Tango Therapeutics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.